


Claims

1. A method of treating or preventing a hyperproliferative disease or disorder or an infectious disease or disorder, the method comprising administering to a subject in need thereof A a compound of formula (I)



wherein:

R^{1A} and R^{1B} are mutually linked to form, together with the nitrogen atom that they are attached to, a heterocycloalkyl which is optionally substituted with one or more groups R^{11} ;

or, alternatively, R^{1A} and R^{1B} are each independently selected from hydrogen, C_{1-5} alkyl, C_{2-5} alkenyl, C_{2-5} alkynyl, $-\text{CO}(C_{1-5} \text{ alkyl})$, carbocyclyl, and heterocyclyl, wherein said alkyl, said alkenyl, said alkynyl, and the alkyl moiety of said $-\text{CO}(C_{1-5} \text{ alkyl})$ are each optionally substituted with one or more groups R^{12} , and further wherein said carbocyclyl and said heterocyclyl are each optionally substituted with one or more groups R^{13} ;

each R^{11} is independently selected from C_{1-5} alkyl, C_{2-5} alkenyl, C_{2-5} alkynyl, $-(C_{0-3} \text{ alkylene})-\text{OH}$, $-(C_{0-3} \text{ alkylene})-\text{O}(C_{1-5} \text{ alkyl})$, $-(C_{0-3} \text{ alkylene})-\text{O}(C_{1-5} \text{ alkylene})-\text{OH}$, $-(C_{0-3} \text{ alkylene})-\text{O}(C_{1-5} \text{ alkylene})-\text{O}(C_{1-5} \text{ alkyl})$, $-(C_{0-3} \text{ alkylene})-\text{SH}$, $-(C_{0-3} \text{ alkylene})-\text{S}(C_{1-5} \text{ alkyl})$, $-(C_{0-3} \text{ alkylene})-\text{NH}_2$, $-(C_{0-3} \text{ alkylene})-\text{NH}(C_{1-5} \text{ alkyl})$, $-(C_{0-3} \text{ alkylene})-\text{N}(C_{1-5} \text{ alkyl})(C_{1-5} \text{ alkyl})$, $-(C_{0-3} \text{ alkylene})-\text{halogen}$, $-(C_{0-3} \text{ alkylene})-(C_{1-5} \text{ haloalkyl})$, $-(C_{0-3} \text{ alkylene})-\text{O}(C_{1-5} \text{ haloalkyl})$, $-(C_{0-3} \text{ alkylene})-\text{CF}_3$, $-(C_{0-3} \text{ alkylene})-\text{CN}$, $-(C_{0-3} \text{ alkylene})-\text{NO}_2$, $-(C_{0-3} \text{ alkylene})-\text{CHO}$, $-(C_{0-3}$

alkylene)-CO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-COOH, -(C₀₋₃ alkylene)-CO-O-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-O-CO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-CO-NH₂, -(C₀₋₃ alkylene)-CO-NH(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-CO-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-NH-CO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-N(C₁₋₅ alkyl)-CO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SO₂-NH₂, -(C₀₋₃ alkylene)-SO₂-NH(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SO₂-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-NH-SO₂-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-N(C₁₋₅ alkyl)-SO₂-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SO₂-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-carbocyclyl, and -(C₀₋₃ alkylene)-heterocyclyl, wherein the carbocyclyl moiety of said -(C₀₋₃ alkylene)-carbocyclyl and the heterocyclyl moiety of said -(C₀₋₃ alkylene)-heterocyclyl are each optionally substituted with one or more groups independently selected from C₁₋₅ alkyl, C₂₋₅ alkenyl, C₂₋₅ alkynyl, -OH, -O(C₁₋₅ alkyl), -O(C₁₋₅ alkylene)-OH, -O(C₁₋₅ alkylene)-O(C₁₋₅ alkyl), -SH, -S(C₁₋₅ alkyl), -NH₂, -NH(C₁₋₅ alkyl), -N(C₁₋₅ alkyl)(C₁₋₅ alkyl), halogen, C₁₋₅ haloalkyl, -O-(C₁₋₅ haloalkyl), -CF₃, -CN, -NO₂, -CHO, -CO-(C₁₋₅ alkyl), -COOH, -CO-O-(C₁₋₅ alkyl), -O-CO-(C₁₋₅ alkyl), -CO-NH₂, -CO-NH(C₁₋₅ alkyl), -CO-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -NH-CO-(C₁₋₅ alkyl), -N(C₁₋₅ alkyl)-CO-(C₁₋₅ alkyl), -SO₂-NH₂, -SO₂-NH(C₁₋₅ alkyl), -SO₂-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -NH-SO₂-(C₁₋₅ alkyl), -N(C₁₋₅ alkyl)-SO₂-(C₁₋₅ alkyl), -SO-(C₁₋₅ alkyl), -SO₂-(C₁₋₅ alkyl), cycloalkyl, and heterocycloalkyl;

each R¹² is independently selected from -OH, -O(C₁₋₅ alkyl), -O(C₁₋₅ alkylene)-OH, -O(C₁₋₅ alkylene)-O(C₁₋₅ alkyl), -SH, -S(C₁₋₅ alkyl), -NH₂, -NH(C₁₋₅ alkyl), -N(C₁₋₅ alkyl)(C₁₋₅ alkyl), halogen, C₁₋₅ haloalkyl, -O-(C₁₋₅ haloalkyl), -CF₃, -CN, -NO₂, -CHO, -CO-(C₁₋₅ alkyl), -COOH, -CO-O-(C₁₋₅ alkyl), -O-CO-(C₁₋₅ alkyl), -CO-NH₂, -CO-NH(C₁₋₅ alkyl), -CO-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -NH-CO-(C₁₋₅ alkyl), -N(C₁₋₅ alkyl)-CO-(C₁₋₅ alkyl), -SO₂-NH₂, -SO₂-NH(C₁₋₅ alkyl), -SO₂-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -NH-SO₂-(C₁₋₅ alkyl), -N(C₁₋₅ alkyl)-SO₂-(C₁₋₅ alkyl), -SO-(C₁₋₅ alkyl), -SO₂-(C₁₋₅ alkyl), cycloalkyl, and heterocycloalkyl;

each R¹³ is independently selected from C₁₋₅ alkyl, C₂₋₅ alkenyl, C₂₋₅ alkynyl, -(C₀₋₃ alkylene)-OH, -(C₀₋₃ alkylene)-O(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-O(C₁₋₅ alkylene)-OH, -(C₀₋₃ alkylene)-O(C₁₋₅ alkylene)-O(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SH, -(C₀₋₃ alkylene)-S(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-NH₂, -(C₀₋₃ alkylene)-NH(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-halogen, -(C₀₋₃ alkylene)-(C₁₋₅ haloalkyl), -(C₀₋₃ alkylene)-O-(C₁₋₅ haloalkyl), -(C₀₋₃ alkylene)-CF₃, -(C₀₋₃

alkylene)-CN, -(C₀₋₃ alkylene)-NO₂, -(C₀₋₃ alkylene)-CHO, -(C₀₋₃ alkylene)-CO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-COOH, -(C₀₋₃ alkylene)-CO-O-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-O-CO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-CO-NH₂, -(C₀₋₃ alkylene)-CO-NH(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-CO-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-NH-CO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-N(C₁₋₅ alkyl)-CO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SO₂-NH₂, -(C₀₋₃ alkylene)-SO₂-NH(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SO₂-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-NH-SO₂-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-N(C₁₋₅ alkyl)-SO₂-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SO₂-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-cycloalkyl, and -(C₀₋₃ alkylene)-heterocycloalkyl;

R² and R⁴ are each independently selected from hydrogen, C₁₋₅ alkyl, C₂₋₅ alkenyl, C₂₋₅ alkynyl, -(C₀₋₃ alkylene)-OH, -(C₀₋₃ alkylene)-O(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-O(C₁₋₅ alkylene)-OH, -(C₀₋₃ alkylene)-O(C₁₋₅ alkylene)-O(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SH, -(C₀₋₃ alkylene)-S(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-NH₂, -(C₀₋₃ alkylene)-NH(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-halogen, -(C₀₋₃ alkylene)-(C₁₋₅ haloalkyl), -(C₀₋₃ alkylene)-O-(C₁₋₅ haloalkyl), -(C₀₋₃ alkylene)-CF₃, -(C₀₋₃ alkylene)-CN, -(C₀₋₃ alkylene)-NO₂, -(C₀₋₃ alkylene)-CHO, -(C₀₋₃ alkylene)-CO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-COOH, -(C₀₋₃ alkylene)-CO-O-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-O-CO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-CO-NH₂, -(C₀₋₃ alkylene)-CO-NH(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-CO-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-NH-CO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-N(C₁₋₅ alkyl)-CO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SO₂-NH₂, -(C₀₋₃ alkylene)-SO₂-NH(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SO₂-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-NH-SO₂-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-N(C₁₋₅ alkyl)-SO₂-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SO₂-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-carbocyclyl, and -(C₀₋₃ alkylene)-heterocyclyl, wherein the carbocyclyl moiety of said -(C₀₋₃ alkylene)-carbocyclyl and the heterocyclyl moiety of said -(C₀₋₃ alkylene)-heterocyclyl are each optionally substituted with one or more groups independently selected from C₁₋₅ alkyl, C₂₋₅ alkenyl, C₂₋₅ alkynyl, -OH, -O(C₁₋₅ alkyl), -O(C₁₋₅ alkylene)-OH, -O(C₁₋₅ alkylene)-O(C₁₋₅ alkyl), -SH, -S(C₁₋₅ alkyl), -NH₂, -NH(C₁₋₅ alkyl), -N(C₁₋₅ alkyl)(C₁₋₅ alkyl), halogen, C₁₋₅ haloalkyl, -O-(C₁₋₅ haloalkyl), -CF₃, -CN, -NO₂, -CHO, -CO-(C₁₋₅ alkyl), -COOH, -CO-O-(C₁₋₅ alkyl), -O-CO-(C₁₋₅ alkyl), -CO-NH₂, -CO-NH(C₁₋₅ alkyl), -CO-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -NH-CO-(C₁₋₅ alkyl), -N(C₁₋₅ alkyl)-CO-(C₁₋₅ alkyl), -SO₂-NH₂, -SO₂-NH(C₁₋₅ alkyl), -SO₂-N(C₁₋₅

alkyl)(C₁₋₅ alkyl), -NH-SO₂-(C₁₋₅ alkyl), -N(C₁₋₅ alkyl)-SO₂-(C₁₋₅ alkyl), -SO-(C₁₋₅ alkyl), -SO₂-(C₁₋₅ alkyl), cycloalkyl, and heterocycloalkyl;

R³ is selected from hydrogen, C₁₋₅ alkyl, C₂₋₅ alkenyl, C₂₋₅ alkynyl, -(C₁₋₅ alkylene)-OH, -(C₁₋₅ alkylene)-O(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-O(C₁₋₅ alkylene)-OH, -(C₁₋₅ alkylene)-O(C₁₋₅ alkylene)-O(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-SH, -(C₁₋₅ alkylene)-S(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-NH₂, -(C₁₋₅ alkylene)-NH(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-halogen, C₁₋₅ haloalkyl, -(C₁₋₅ alkylene)-O-(C₁₋₅ haloalkyl), -(C₁₋₅ alkylene)-CF₃, -(C₁₋₅ alkylene)-CN, -(C₁₋₅ alkylene)-NO₂, -(C₁₋₅ alkylene)-Si(C₁₋₅ alkyl)₃, -(C₁₋₅ alkylene)-O(C₁₋₅ alkylene)-Si(C₁₋₅ alkyl)₃, -(C₁₋₅ alkylene)-CHO, -(C₁₋₅ alkylene)-CO-(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-COOH, -(C₁₋₅ alkylene)-CO-O-(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-O-CO-(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-CO-NH₂, -(C₁₋₅ alkylene)-CO-NH(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-CO-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-NH-CO-(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-N(C₁₋₅ alkyl)-CO-(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-NH-CO-O-(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-N(C₁₋₅ alkyl)-CO-O-(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-O-CO-NH-(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-O-CO-N(C₁₋₅ alkyl)-(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-SO₂-NH₂, -(C₁₋₅ alkylene)-SO₂-NH(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-SO₂-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-NH-SO₂-(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-N(C₁₋₅ alkyl)-SO₂-(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-SO-(C₁₋₅ alkyl), -(C₁₋₅ alkylene)-SO₂-(C₁₋₅ alkyl), -(C₀₋₅ alkylene)-carbocyclyl, and -(C₀₋₅ alkylene)-heterocyclyl, wherein the carbocyclyl moiety of said -(C₀₋₅ alkylene)-carbocyclyl and the heterocyclyl moiety of said -(C₀₋₅ alkylene)-heterocyclyl are each optionally substituted with one or more groups independently selected from C₁₋₅ alkyl, C₂₋₅ alkenyl, C₂₋₅ alkynyl, -OH, -O(C₁₋₅ alkyl), -O(C₁₋₅ alkylene)-OH, -O(C₁₋₅ alkylene)-O(C₁₋₅ alkyl), -SH, -S(C₁₋₅ alkyl), -NH₂, -NH(C₁₋₅ alkyl), -N(C₁₋₅ alkyl)(C₁₋₅ alkyl), halogen, C₁₋₅ haloalkyl, -O-(C₁₋₅ haloalkyl), -CF₃, -CN, -NO₂, -CHO, -CO-(C₁₋₅ alkyl), -COOH, -CO-O-(C₁₋₅ alkyl), -O-CO-(C₁₋₅ alkyl), -CO-NH₂, -CO-NH(C₁₋₅ alkyl), -CO-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -NH-CO-(C₁₋₅ alkyl), -N(C₁₋₅ alkyl)-CO-(C₁₋₅ alkyl), -NH-CO-O-(C₁₋₅ alkyl), -N(C₁₋₅ alkyl)-CO-O-(C₁₋₅ alkyl), -O-CO-NH-(C₁₋₅ alkyl), -O-CO-N(C₁₋₅ alkyl)-(C₁₋₅ alkyl), -SO₂-NH₂, -SO₂-NH(C₁₋₅ alkyl), -SO₂-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -NH-SO₂-(C₁₋₅ alkyl), -N(C₁₋₅ alkyl)-SO₂-(C₁₋₅ alkyl), -SO-(C₁₋₅ alkyl), -SO₂-(C₁₋₅ alkyl), cycloalkyl, and heterocycloalkyl.

L is C₁₋₅ alkylene, wherein one or more -CH₂- units comprised in said alkylene are each optionally replaced by a group independently selected from -N(R^L)-, -N(R^L)-CO-, -CO-N(R^L)-, -CO-, -O-, -CO-O-, -O-CO-, -S-, -SO-, -SO₂-, -SO₂-N(R^L)-, and -N(R^L)-SO₂-;

each R^L is independently selected from hydrogen and C₁₋₅ alkyl;


ring A is aryl or monocyclic heteroaryl, wherein said aryl or said monocyclic heteroaryl is optionally substituted with one or more groups R^A; and

each R^A is independently selected from C₁₋₅ alkyl, C₂₋₅ alkenyl, C₂₋₅ alkynyl, -(C₀₋₃ alkylene)-OH, -(C₀₋₃ alkylene)-O(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-O(C₁₋₅ alkylene)-OH, -(C₀₋₃ alkylene)-O(C₁₋₅ alkylene)-O(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SH, -(C₀₋₃ alkylene)-S(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-NH₂, -(C₀₋₃ alkylene)-NH(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-halogen, -(C₀₋₃ alkylene)-(C₁₋₅ haloalkyl), -(C₀₋₃ alkylene)-O-(C₁₋₅ haloalkyl), -(C₀₋₃ alkylene)-CF₃, -(C₀₋₃ alkylene)-CN, -(C₀₋₃ alkylene)-NO₂, -(C₀₋₃ alkylene)-CHO, -(C₀₋₃ alkylene)-CO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-COOH, -(C₀₋₃ alkylene)-CO-O-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-O-CO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-CO-NH₂, -(C₀₋₃ alkylene)-CO-NH(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-CO-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-NH-CO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-N(C₁₋₅ alkyl)-CO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SO₂-NH₂, -(C₀₋₃ alkylene)-SO₂-NH(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SO₂-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-NH-SO₂-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-N(C₁₋₅ alkyl)-SO₂-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SO-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-SO₂-(C₁₋₅ alkyl), -(C₀₋₃ alkylene)-carbocyclyl, and -(C₀₋₃ alkylene)-heterocyclyl, wherein the carbocyclyl moiety of said -(C₀₋₃ alkylene)-carbocyclyl and the heterocyclyl moiety of said -(C₀₋₃ alkylene)-heterocyclyl are each optionally substituted with one or more groups independently selected from C₁₋₅ alkyl, C₂₋₅ alkenyl, C₂₋₅ alkynyl, -OH, -O(C₁₋₅ alkyl), -O(C₁₋₅ alkylene)-OH, -O(C₁₋₅ alkylene)-O(C₁₋₅ alkyl), -SH, -S(C₁₋₅ alkyl), -NH₂, -NH(C₁₋₅ alkyl), -N(C₁₋₅ alkyl)(C₁₋₅ alkyl), halogen, C₁₋₅ haloalkyl, -O-(C₁₋₅ haloalkyl), -CF₃, -CN, -NO₂, -CHO, -CO-(C₁₋₅ alkyl), -COOH, -CO-O-(C₁₋₅ alkyl), -O-CO-(C₁₋₅ alkyl), -CO-NH₂, -CO-NH(C₁₋₅ alkyl), -CO-N(C₁₋₅ alkyl)(C₁₋₅ alkyl), -NH-CO-(C₁₋₅ alkyl), -N(C₁₋₅ alkyl)-CO-(C₁₋₅ alkyl), -SO₂-NH₂, -SO₂-NH(C₁₋₅ alkyl), -SO₂-N(C₁₋₅ alkyl)(C₁₋₅

alkyl), -NH-SO₂-(C₁₋₅ alkyl), -N(C₁₋₅ alkyl)-SO₂-(C₁₋₅ alkyl), -SO-(C₁₋₅ alkyl), -SO₂-(C₁₋₅ alkyl), cycloalkyl, and heterocycloalkyl;

or a pharmaceutically acceptable salt, solvate or prodrug thereof.

2. ~~The compound of claim 1, wherein R^{1A} and R^{1B} are mutually linked to form, together with the nitrogen atom that they are attached to, a group which is selected from~~



~~wherein each one of the above depicted groups is optionally substituted with one or more R¹¹.~~

3. ~~The compound of claim 1 or 2, wherein R² and R⁴ are each independently selected from hydrogen, C₁₋₅ alkyl, OH, O(C₁₋₅ alkyl), O(C₁₋₅ alkylene) OH, O(C₁₋₅ alkylene) O(C₁₋₅ alkyl), SH, S(C₁₋₅ alkyl), NH, NH(C₁₋₅ alkyl), N(C₁₋₅ alkyl)(C₁₋₅ alkyl), halogen, C₁₋₅ haloalkyl, CF₃, and CN.~~
4. ~~The compound of any one of claims 1 to 3, wherein R³ is CH₂CF₃ or CH₂SO₂CH₃.~~
5. ~~The compound of any one of claims 1 to 4, wherein L is C₁₋₃ alkylene, wherein one CH₂ unit comprised in said alkylene is optionally replaced by a group selected from N(R^L), N(R^L) CO, CO N(R^L), and CO, and further wherein each R^L is independently selected from hydrogen, methyl and ethyl.~~
6. ~~The compound of any one of claims 1 to 5, wherein L is NH.~~
7. ~~The compound of any one of claims 1 to 6, wherein ring A is phenyl or a 6-membered monocyclic heteroaryl, wherein said phenyl or said monocyclic heteroaryl is optionally substituted with one or more groups R^A; wherein it is preferred that ring A is selected from phenyl, pyridinyl, pyrimidinyl, and pyrazinyl, wherein said phenyl, said pyridinyl, said pyrimidinyl and said pyrazinyl are each optionally substituted with one or more groups R^A.~~

8. ~~The compound of any one of claims 1 to 7, wherein ring A is phenyl or pyridin-2-yl, wherein said phenyl or said pyridin-2-yl is optionally substituted with one or more groups R^A:~~
9. ~~The compound of any one of claims 1 to 8, wherein each R^A is independently selected from C₁₋₅-alkyl, OH, O(C₁₋₅-alkyl), O(C₁₋₅-alkylene) OH, O(C₁₋₅-alkylene) O(C₁₋₅-alkyl), SH, S(C₁₋₅-alkyl), NH₂, NH(C₁₋₅-alkyl), N(C₁₋₅-alkyl)(C₁₋₅-alkyl), halogen, C₁₋₅-haloalkyl, CF₃, and CN; preferably wherein each R^A is independently halogen; and more preferably wherein each R^A is F.~~
10. ~~The compound of claim 1, wherein said compound is selected from:~~

1	~~[3-(2-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone~~
2	~~[3-anilino-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone~~
3	~~[3-(2-methoxyanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone~~
4	~~[3-(2-methylanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone~~
5	~~[3-(N-methylanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone~~
6	~~[3-(3-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone~~
7	~~[3-(3-methoxyanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone~~
8	~~3-[[6-(1,4-oxazepan-4-carbonyl)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-3-yl]amino]benzonitrile~~
9	~~3-[[6-(1,4-oxazepan-4-carbonyl)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-3-yl]amino]benzamide~~
10	~~[3-(4-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone~~
11	~~[3-(4-methoxyanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone~~

12	1,4-oxazepan-4-yl-[3-(3-pyridylamino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone
13	4-[[6-(1,4-oxazepan-4-carbonyl)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-3-yl]amino]benzonitrile
14	4-[[6-(1,4-oxazepan-4-carbonyl)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-3-yl]amino]benzamide
15	[3-(3,5-difluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
16	[3-(3-fluoro-4-methylanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
17	[3-(3,4-difluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
18	[3-(3-chloro-4-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
19	[3-(4-chloro-3-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
20	[3-(3-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)methanone
21	[3-(4-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)methanone
22	[3-(4-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(4-hydroxy-1-piperidyl)methanone
23	[3-(3-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(4-hydroxy-1-piperidyl)methanone
24	(4-hydroxy-1-piperidyl)-[3-(2-pyridylamino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone
25	[3-(3-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(3- <i>endo</i> -hydroxy-8-azabicyclo[3.2.1]octan-8-yl)methanone
26	[3-(4-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(3- <i>endo</i> -hydroxy-8-azabicyclo[3.2.1]octan-8-yl)methanone
27	[3-(4-fluoroanilino)-1-(methylsulfonylmethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
28	[3-(3-fluoroanilino)-1-(methylsulfonylmethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone

29	[3-anilino-1-(methylsulfonylmethyl)pyrazolo[4,3-c]pyridin-6-yl]-(3- <i>endo</i> -hydroxy-8-azabicyclo[3.2.1]octan-8-yl)methanone
30	[3-(4-fluoroanilino)-1-(methylsulfonylmethyl)pyrazolo[4,3-c]pyridin-6-yl]-(3- <i>endo</i> -hydroxy-8-azabicyclo[3.2.1]octan-8-yl)methanone
31	[3-(3-fluoroanilino)-1-(methylsulfonylmethyl)pyrazolo[4,3-c]pyridin-6-yl]-(3- <i>endo</i> -hydroxy-8-azabicyclo[3.2.1]octan-8-yl)methanone
32	[3-(3-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(6-hydroxy-1,4-oxazepan-4-yl)methanone
33	[3-(4-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(6-hydroxy-1,4-oxazepan-4-yl)methanone
34	[3-(4-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(4-hydroxy-4-methyl-1-piperidyl)methanone
35	[3-(3-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(4-hydroxy-4-methyl-1-piperidyl)methanone
36	1,4-oxazepan-4-yl-[3-(pyrimidin-2-ylamino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone
37	[3-(3-chloroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
38	[3-(4-chloroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
39	[3-(2-chloroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
40	(6,6-dideuterio-1,4-oxazepan-4-yl)-[3-(3-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone
41	(6,6-dideuterio-1,4-oxazepan-4-yl)-[3-(4-fluoroanilino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone
42	1,4-oxazepan-4-yl-[3-(2-pyridylamino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone
43	1,4-oxazepan-4-yl-[3-(4-pyridylamino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone
44	[3-[(5-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
45	[3-[(6-methoxy-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone

46	[3-[(4-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
47	8-oxa-3-azabicyclo[3.2.1]octan-3-yl-[3-(2-pyridylamino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone
48	[3-[(5-chloro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
49	[3-[(6-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
50	[3-[(5-methoxy-3-methyl-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
51	[3-[(6-chloro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
52	(6-hydroxy-1,4-oxazepan-4-yl)-[3-(2-pyridylamino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone
53	(4-hydroxy-4-methyl-1-piperidyl)-[3-(2-pyridylamino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone
54	[3-[(3-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
55	[3-[(3-chloro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
56	[3-[(5-fluoro-3-methyl-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
57	[3-[(5-fluoro-4-methyl-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
58	[3-[(5-fluoro-6-methyl-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
59	(6,6-dideuterio-1,4-oxazepan-4-yl)-[3-(2-pyridylamino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone
60	(6,6-dideuterio-1,4-oxazepan-4-yl)-[3-[(4-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone
61	1,4-oxazepan-4-yl-[3-(pyrazin-2-ylamino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone
62	1,4-oxazepan-4-yl-[1-(2,2,2-trifluoroethyl)-3-[[4-(trifluoromethyl)-2-

	pyridyl]amino]pyrazolo[4,3-c]pyridin-6-yl]methanone
63	[3-[(4-methoxy-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
64	[3-[(4-chloro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
65	[3-[(6-chloro-5-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
66	[3-[(4-chloro-5-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
67	[3-[(3-chloro-5-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
68	[3-[(4-methyl-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
69	1,4-oxazepan-4-yl-[3-(pyridazin-3-ylamino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone
70	[3-[(4-fluoro-3-methyl-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
71	[3-[(5-chloro-4-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
72	[3-[(3,5-difluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone
73	[1,4]Oxazepan-4-yl-[3-(pyrimidin-4-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-methanone
74	(4-Hydroxy-piperidin-1-yl)-[3-(pyrazin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-methanone
75	[3-(5-Chloro-pyrazin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-(4-hydroxy-piperidin-1-yl)-methanone
76	(4-Hydroxy-piperidin-1-yl)-[3-(pyrimidin-4-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-methanone
77	[3-(5-Fluoro-pyridin-2-ylamino)-1-methanesulfonylmethyl-1H-pyrazolo[4,3-c]pyridin-6-yl]-[1,4]oxazepan-4-yl-methanone
78	[3-(5-Chloro-pyridin-2-ylamino)-1-methanesulfonylmethyl-1H-pyrazolo[4,3-c]pyridin-6-yl]-[1,4]oxazepan-4-yl-methanone

79	~~[3-(4-Chloro-pyridin-2-ylamino)-1-methanesulfonylmethyl-1H-pyrazolo[4,3-c]pyridin-6-yl]-[1,4]oxazepan-4-yl-methanone~~
80	~~[3-[(5,6-difluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone~~
81	~~[3-[(5-fluoro-4-methoxy-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone~~
82	~~[3-[(5-fluoro-6-methoxy-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone~~
83	~~[3-(5-Methoxy-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-[1,4]oxazepan-4-yl-methanone~~
84	~~[1,4]Oxazepan-4-yl-[3-(thiazol-5-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-methanone~~
85	~~[1,4]Oxazepan-4-yl-[3-(thiazol-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-methanone~~
86	~~6-[6-([1,4]Oxazepane-4-carbonyl)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-3-ylamino]-1H-pyridin-2-one~~
87	~~3-[[6-(1,4-oxazepane-4-carbonyl)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-3-yl]amino]-1H-pyridin-2-one~~
88	~~[3-[(5-fluoro-4-hydroxy-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone~~
89	~~[3-[(5-fluoro-3-hydroxy-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone~~
90	~~[3-[(4-fluoro-3-hydroxy-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(1,4-oxazepan-4-yl)methanone~~
91	~~(6,6-dideuterio-1,4-oxazepan-4-yl)-[3-[(5-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone~~
92	~~[3-[(5-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(6-hydroxy-1,4-oxazepan-4-yl)methanone~~
93	~~[(6S)-6-fluoro-1,4-oxazepan-4-yl]-[3-[(5-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone~~
94	~~[3-[(5-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(4-hydroxypiperidin-1-yl)methanone~~
95	~~[3-(5-Fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-~~

	c]pyridin-6-yl)-(4-hydroxy-4-methyl-piperidin-1-yl)-methanone
96	~~(4-Fluoro-piperidin-1-yl)-[3-(5-fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-methanone~~
97	~~[(3<i>R</i>)-3-hydroxy-piperidin-1-yl]-[3-(5-Fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]methanone~~
98	~~[(3<i>S</i>)-3-hydroxy-piperidin-1-yl]-[3-(5-Fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]methanone~~
99	~~[(3<i>R</i>)-3-fluoro-piperidin-1-yl]-[3-(5-Fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]methanone~~
100	~~[(3<i>S</i>)-3-fluoro-piperidin-1-yl]-[3-(5-Fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]methanone~~
101	~~[3-[(5-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-[(3<i>R</i>)-3-(hydroxymethyl)-1-piperidyl]methanone~~
102	~~[3-[(5-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-[(3<i>S</i>)-3-(hydroxymethyl)-1-piperidyl]methanone~~
103	~~(3,3-Difluoro-4-hydroxy-piperidin-1-yl)-[3-(5-fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-methanone~~
104	~~[3-[(5-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-[3-hydroxy-3-methyl-piperidin-1-yl]methanone~~
105	~~<i>Cis</i>-[3-(5-Fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-[3-hydroxy-4-methyl-piperidin-1-yl]-methanone~~
106	~~<i>Cis</i>-(3-Fluoro-4-hydroxy-piperidin-1-yl)-[3-(5-fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-methanone~~
107	~~[3-[(5-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-[3-<i>endo</i>-hydroxy-8-azabicyclo[3.2.1]octan-8-yl]methanone~~
108	~~1-[3-[(5-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridine-6-carbonyl]pyridine-4-carboxylic acid~~
109	~~[3-[(4-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-[6-hydroxy-1,4-oxazepan-4-yl]methanone~~
110	~~[(6<i>S</i>)-6-fluoro-1,4-oxazepan-4-yl]-[3-(4-fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-methanone~~

111	[3-[(4-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(4-hydroxypiperidin-1-yl)methanone
112	[3-(4-Fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-(4-hydroxy-4-methyl-piperidin-1-yl)-methanone
113	[3-(4-Fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-(4-ethyl-4-hydroxypiperidin-1-yl)-methanone
114	[3-(4-Fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-(4-isopropyl-4-hydroxypiperidin-1-yl)-methanone
115	[3-(4-Fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-(4-cyclopropyl-4-hydroxypiperidin-1-yl)-methanone
116	(4-Fluoro-piperidin-1-yl)-[3-(4-fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-methanone
117	[(3S)-3-hydroxy-piperidin-1-yl]-[3-(4-fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]methanone
118	[3-(4-Fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-(4-hydroxy-2,2-dimethyl-piperidin-1-yl)-methanone
119	(3,3-Difluoro-4-hydroxy-piperidin-1-yl)-[3-(4-fluoro-pyridin-2-ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-methanone
120	[3-[(4-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]-(3-endo-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)methanone
121	6,6-dideuterio-1,4-oxazepan-4-yl]-[3-(pyrazin-2ylamino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl]methanone
122	[(6S)-6-fluoro-1,4-oxazepan-4-yl]-[3-(pyrazin-2ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-methanone
123	[3-(pyrazin-2ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-(4-hydroxy-4-methyl-piperidin-1-yl)-methanone
124	[3-(pyrazin-2ylamino)-1-(2,2,2-trifluoro-ethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]-(4-fluoro-piperidin-1-yl)-methanone
125	[3-[(5-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl] [(2R)-2-(2-hydroxy-2-methyl-propyl)pyrrolidin-1-yl]methanone
126	[3-[(5-fluoro-2-pyridyl)amino]-1-(2,2,2-trifluoroethyl)pyrazolo[4,3-c]pyridin-6-yl] [(2S)-2-(2-hydroxy-2-methyl-propyl)pyrrolidin-1-

	yl]methanone
127	(3- <i>endo</i> -hydroxy-8-azabicyclo[3.2.1]octan-8-yl)-[3-(2-pyridylamino)-1-(2,2,2-trifluoroethyl)pyrazolo[4,3- <i>c</i>]pyridin-6-yl]methanone

and pharmaceutically acceptable salts, solvates and prodrugs of any one of the aforementioned compounds.

11. The compound of any one of claims 1 to 10 for use as a medicament.
12. A pharmaceutical composition comprising the compound of any one of claims 1 to 10 and a pharmaceutically acceptable excipient.
13. The compound of any one of claims 1 to 10 or the pharmaceutical composition of claim 12 for use in therapy as a dual adenosine A_{2A}- and A_{2B}-receptor antagonist.
14. The compound of any one of claims 1 to 10 or 13 or the pharmaceutical composition of claim 12 or 13 for use in the treatment or prevention of a hyperproliferative disease or disorder or an infectious disease or disorder.
15. Use of the compound of any one of claims 1 to 10 in the preparation of a medicament for the treatment or prevention of a hyperproliferative disease or disorder or an infectious disease or disorder.
16. A method of treating or preventing a hyperproliferative disease or disorder or an infectious disease or disorder, the method comprising administering the compound of claim 1 to a subject in need thereof.
17. The compound for use according to claim 14 or the pharmaceutical composition for use according to claim 14 or the use of claim 15 or the method of claim 16, wherein the disease or disorder to be treated or prevented is a hyperproliferative disease or disorder, and wherein said hyperproliferative disease or disorder is cancer.
18. The compound for use according to claim 17 or the pharmaceutical composition for use according to claim 17 or the use of claim 17 or the method of claim 17,

wherein the cancer is selected from the group consisting of acute granulocytic leukemia, acute lymphocytic leukemia, acute myeloid leukemia, adrenal cortex cancer, bladder cancer, brain cancer, breast cancer, cervical cancer, cervical hyperplasia, cervical cancer, chorio cancer, chronic granulocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, colon cancer, endometrial cancer, esophageal cancer, essential thrombocytosis, genitourinary carcinoma, glioma, glioblastoma, hairy cell leukemia, head and neck carcinoma, Hodgkin's disease, Kaposi's sarcoma, lung carcinoma, lymphoma, malignant carcinoid carcinoma, malignant hypercalcemia, malignant melanoma, malignant pancreatic insulinoma, medullary thyroid carcinoma, melanoma, multiple myeloma, mycosis fungoides, neuroblastoma, non-Hodgkin's lymphoma, non-small cell lung cancer, osteogenic sarcoma, ovarian carcinoma, pancreatic carcinoma, polycythemia vera, primary brain carcinoma, primary macroglobulinemia, prostatic cancer, renal cell cancer, rhabdomyosarcoma, skin cancer, small cell lung cancer, soft tissue sarcoma, squamous cell cancer, stomach cancer, testicular cancer, thyroid cancer and Wilms' tumor.

19. The compound for use according to claim 14 or the pharmaceutical composition for use according to claim 14 or the use of claim 15 or the method of claim 16, wherein the disease or disorder to be treated or prevented is a hyperproliferative disease or disorder, and wherein said hyperproliferative disease or disorder is selected from the group consisting of age-related macular degeneration, Crohn's disease, cirrhosis, a chronic inflammatory-related disorder, proliferative diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, granulomatosis, immune hyperproliferation associated with organ or tissue transplantation, and an immunoproliferative disease or disorder.

20. The compound for use according to claim 19 or the pharmaceutical composition for use according to claim 19 or the use of claim 19 or the method of claim 19, wherein the disease/disorder to be treated or prevented is an immunoproliferative disease or disorder, and wherein the immunoproliferative disease or disorder is selected from the group consisting of inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus (SLE), vascular hyperproliferation secondary to retinal hypoxia, and vasculitis.

21. ~~The compound for use according to claim 14 or the pharmaceutical composition for use according to claim 14 or the use of claim 15 or the method of claim 16, wherein the disease or disorder to be treated or prevented is an infectious disease or disorder, and wherein said infectious disease or disorder is selected from the group consisting of:~~

- ~~(a) virally induced infectious diseases which are caused by retroviruses, hepadnaviruses, herpesviruses, flaviviridae and/or adenoviruses, wherein the retroviruses are selected from lentiviruses or oncoretroviruses, wherein the lentivirus is selected from the group consisting of HIV-1, HIV-2, FIV, BIV, SIVs, SHIV, CAEV, VMV and EIAV, wherein the oncoretrovirus is selected from the group consisting of HTLV-I, HTLV-II and BLV, wherein the hepadnavirus is selected from the group consisting of HBV, GSHV and WHV, wherein the herpesvirus is selected from the group consisting of HSV I, HSV II, EBV, VZV, HCMV and HHV 8, and wherein the flaviviridae are selected from the group consisting of HCV, West nile and Yellow Fever;~~
- ~~(b) bacterial infectious diseases which are caused by Gram-positive bacteria, wherein the Gram-positive bacteria are selected from the group consisting of methicillin-susceptible and methicillin-resistant staphylococci (including Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus, and coagulase-negative staphylococci), glycopeptides-intermediate susceptible Staphylococcus aureus (GISA), penicillin-susceptible and penicillin-resistant streptococci (including Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus avium, Streptococcus bovis, Streptococcus lactis, Streptococcus sanguis and Streptococci Group C (GCS), Streptococci Group G (GGS) and viridans streptococci), enterococci (including vancomycinsusceptible and vancomycin-resistant strains such as Enterococcus faecalis and Enterococcus faecium), Clostridium difficile, Listeria monocytogenes, Corynebacterium jeikeium, Chlamydia spp (including C. pneumoniae) and Mycobacterium tuberculosis;~~
- ~~(c) bacterial infectious diseases which are caused by Gram-negative bacteria, wherein the Gram-negative bacteria are selected from the group consisting of the genus Enterobacteriaceae, including Escherichia spp. (including Escherichia coli), Klebsiella spp., Enterobacter spp., Citrobacter spp., Serratia spp., Proteus spp., Providencia spp., Salmonella spp., Shigella spp.,~~

~~the genus *Pseudomonas* (including *P. aeruginosa*), *Moraxella* spp. (including *M. catarrhalis*), *Haemophilus* spp. and *Neisseria* spp.; and~~

- ~~(d) infectious diseases induced by intracellular active parasites selected from the group consisting of the phylum Apicomplexa, Sarcostigophora (including *Trypanosoma*, *Plasmodia*, *Leishmania*, *Babesia* or *Theileria*), *Cryptosporidia*, *Sarcocystida*, *Amoebia*, *Coccidia* and *Trichomonadia*.~~

~~22. The compound for use according to any one of claims 14 or 17 to 21 or the pharmaceutical composition for use according to any one of claims 14 or 17 to 21 or the use of any one of claims 15 or 17 to 21 or the method of any one of claims 16 to 21, wherein said compound, said pharmaceutical composition or said medicament is to be administered in combination with one or more further therapeutic agents.~~

~~23. The compound for use according to any one of claims 14 or 17 to 22 or the pharmaceutical composition for use according to any one of claims 14 or 17 to 22 or the use of any one of claims 15 or 17 to 22 or the method of any one of claims 16 to 22, wherein the subject to be treated is a human.~~

~~24. A set or kit comprising separate packs of:~~

- ~~— (a) a compound as defined in any one of claims 1 to 10; and
(b) a further therapeutic agent.~~

~~25. *In vitro* use of a compound as defined in any one of claims 1 to 10 as a dual adenosine A_{2A} and A_{2B} receptor antagonist.~~